Phase 1 × Lymphoma, T-Cell, Cutaneous × Cyclophosphamide × Clear all
NCT07055477 2026-02-20

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
60 enrolled
NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
127 enrolled
NCT00641381 2025-05-01

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

City of Hope Medical Center

Phase 1 Active not recruiting
25 enrolled
NCT00004114 2020-07-31

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
NCT00005092 2018-10-26

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
7 enrolled
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00004904 2012-06-04

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Northwestern University

Phase 1 Completed
NCT00062140 2010-09-21

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 1 Completed